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Background: SPECTAlung is a screening program of the European Organization for
the Research and Treatment of Cancer (EORTC) in collaboration with the European
Thoracic Oncology Platform (ETOP) for efficient clinical trial access for patients with
thoracic tumors. Screening for molecular alteration is center/country dependent, and
limited to a small subset of genes. Running clinical trials in small subsets of patients is
challenging also because of lack of uniform testing program. SPECTAlung is the first
European standardized, quality-assured molecular testing platform for thoracic tumor
characterization with the overall goal of giving access to specifically targeted
downstream clinical trials.
Trial design: After consenting, existing tumor tissue will be collected, centralized and
processed according to defined international quality control standards at Gustave
Roussy Biobank (Villejuif, Fr). Next Generation Sequencing (NGS) will be performed
at Sanger Institute (Cambridge, UK) where a panel of 360 genes will be analyzed for
mutations, rearrangements and gene copy number. Eligible patients will be those
having a pathological diagnosis of any thoracic tumor (lung cancer, malignant pleural
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